- Halozyme President and CEO Helen Torley cut direct common-stock holdings to 767,780 shares in transactions dated April 1-2.
- Torley sold 40,000 shares at weighted average prices of $64.06-$65.71.
- She exercised options for 40,000 shares at $12.07 per share.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001159036-26-000046), on April 02, 2026, and is solely responsible for the information contained therein.
Comments